Andere Sprachen ZYUS Life Sciences Corporation

Aktien

A3EGH0

CA9899601095

ZYUS

Verzögert Toronto S.E. Andere Börsenplätze 20:52:16 10.05.2024			% 5 Tage	% 1. Jan.
1,11 ^CAD	-5,13 %		+5,71 %	+23,33 %

07.05.	ZYUS Life Sciences Corporation meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
01.02.	Zyus ernennt Dr. Hance Clarke zum klinischen Beirat	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ZYUS Announces Completion of Its Annual Filings	08.05.
INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9	08.05.
ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	07.05.
ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	23.04.
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management	23.04.
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	05.03.
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	20.02.
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	20.02.
ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke	02.02.
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee	01.02.
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee	01.02.
ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research	10.01.
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Management	06.12.
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care	05.12.
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management	05.12.
ZYUS Life Sciences Corporation Reports Q3 2023 Results	30.11.
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30.11.
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin Softgels	22.11.
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels	21.11.
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels	21.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ZYUS Life Sciences Corporation

Aktien

A3EGH0

CA9899601095

ZYUS

Andere Sprachen

Filter